

产品名称: TP-0903  
 产品别名: Duberminib

生物活性:					
<b>Description</b>	Duberminib (TP-0903) is a potent and selective <b>Axl</b> receptor tyrosine kinase inhibitor with an <b>IC<sub>50</sub></b> value of 27 nM.				
<b>IC<sub>50</sub> &amp; Target</b>	IC50: 27nM (Axl)[1]				
<b>In Vitro</b>	Duberminib (TP-0903) displays a potent activity against AXL with an IC50 of 0.027 μM. Duberminib (TP-0903) shows extremely potent activity in cell viability assays with an IC50 of 6 nM against the pancreatic cancer cell line PSN-1. Duberminib (TP-0903) is evaluated for its ability to block GAS6-mediated activation of AXL in pancreatic cancer cells. PSN-1 cells are serum-starved and then stimulated with GAS6 in the presence of various concentrations of TP-0903[1].				
<b>Solvent&amp;Solubility</b>	<b>In Vitro:</b> DMSO : ≥ 30 mg/mL (58.13 mM) * "≥" means soluble, but saturation unknown.				
		Solvent / Mass Concentration	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
	<b>Preparing</b>	1 mM	1.9378 mL	9.6888 mL	19.3776 mL
	<b>Stock Solutions</b>	5 mM	0.3876 mL	1.9378 mL	3.8755 mL
		10 mM	0.1938 mL	0.9689 mL	1.9378 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液, 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。				
<b>References</b>	[1]. Mollard A, et al. <u>Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors</u> . ACS Med Chem Lett. 2011 Dec 8;2(12):907-912.				
实验参考:					
<b>Cell Assay</b>	For cell proliferation assays, 45 μL containing 1000 cells per well are seeded into solid white 384-well plates in appropriate media. The following day, Duberminib (TP-0903) is diluted in serum free growth media to 10x desired concentrations and 5 μL is added to each well. Combined compound and cells are incubated for 96 hours. Following incubation, 40 μL of ATP-Lite solution is added to each well, incubated for an additional 10 minutes at room temperature and luminescence is measured on a microplate reader[1].				
<b>References</b>	[1]. Mollard A, et al. <u>Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors</u> . ACS Med Chem Lett. 2011 Dec 8;2(12):907-912.				